UniProtKB/Swiss-Prot Q8TEQ8: Variant p.Thr130Asn

GPI ethanolamine phosphate transferase 3
Gene: PIGO
Feedback?

Variant information Variant position:

130 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Threonine (T) to Asparagine (N) at position 130 (T130N, p.Thr130Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and polar. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Found in a patient with epileptic encephalopathy; likely pathogenic; decrease in mannose-ethanolamine phosphotransferase activity; decreased protein expression. Any additional useful information about the variant.

Sequence information Variant position:

130 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

1089 The length of the canonical sequence.
Location on the sequence:

ILEIQPHHARLYRSQVDPPT T TMQRLKALTTGSLPTFIDAG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ILEIQPHHARLYRSQVDPPTTTMQRLKALTTGSLPTFIDAG

Mouse                         ILESQPHHGRLYRSQVDPPTTTMQRLKALTTGSLPTFIDAG

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 1089	GPI ethanolamine phosphate transferase 3

Literature citations
PIGO mutations in intractable epilepsy and severe developmental delay with mild elevation of alkaline phosphatase levels.
Nakamura K.; Osaka H.; Murakami Y.; Anzai R.; Nishiyama K.; Kodera H.; Nakashima M.; Tsurusaki Y.; Miyake N.; Kinoshita T.; Matsumoto N.; Saitsu H.;
Epilepsia 55:E13-E17(2014)
Cited for: VARIANT ASN-130; Phenotype-genotype correlations of PIGO deficiency with variable phenotypes from infantile lethality to mild learning difficulties.
Tanigawa J.; Mimatsu H.; Mizuno S.; Okamoto N.; Fukushi D.; Tominaga K.; Kidokoro H.; Muramatsu Y.; Nishi E.; Nakamura S.; Motooka D.; Nomura N.; Hayasaka K.; Niihori T.; Aoki Y.; Nabatame S.; Hayakawa M.; Natsume J.; Ozono K.; Kinoshita T.; Wakamatsu N.; Murakami Y.;
Hum. Mutat. 38:805-815(2017)
Cited for: VARIANTS HPMRS2 LYS-344; SER-370; 430-GLN--ARG-1089 DEL AND GLU-1047; CHARACTERIZATION OF VARIANTS HPMRS2 TRP-119; LYS-344; SER-370; PHE-957 AND GLU-1047; CHARACTERIZATION OF ASN-130; FUNCTION;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.